go-v.orgdoi

Lacosamide as a new add-on therapy for the treatment of partial-onset seizures

Steve S. Chung · Clinical Investigation · 2011

  • DOI 10.4155/cli.10.2
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2011

Abstract

Lacosamide (LCM) is a recently approved anticonvulsant in Europe and the USA. Efficacy data showed fast onset of anticonvulsant effects and significant reduction of partial-onset seizures, even in a severely refractory population. LCM is well tolerated, with the most common adverse event being dizziness, followed by headache, nausea and diplopia. LCM also provides a novel mechanism of action and favorable pharmacokinetic profile that includes absolute bioavailability, low protein binding, renal excretion, lack of hepatic enzyme induction or inhibition, low potential for drug–drug interactions, and a relatively long half-life.

LCM can also be given as intravenous solution without significant cardiac side effects. Considering the fact that more than 30% of epilepsy patients remain refractory despite various anti-epileptic drugs, LCM may provide added benefit to patients with refractory seizures.

Open the resolved locator · 10.4155/cli.10.2

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:14 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.10.2
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.